Can we measure the risk of cancer in new-onset IIM?Can we further stratify the risk in patients with specific phenotypes? (e.g., different autoantibodies associated with DM, ASyS)Can we better stratify patients at high risk according to disease phenotypes and autoantibodies? (e.g., anti-TIF1γ DM who do not develop cancer)Can we assess the risk of IIM in patients newly diagnosed with cancer? Here, TRIM33 is linked to cancer.